Patents Assigned to PHAROSGEN
  • Doppel-targeting antibodies
    Patent number: 11912760
    Abstract: Described herein are doppel-targeting molecules (e.g., antibodies) useful for inhibiting pathological angiogenesis and treating diseases and conditions associated with pathological angiogenesis, such as tumors, cancers, atherosclerosis, tuberculosis, asthma, pulmonary arterial hypertension (PAH), neoplasms and neoplasm-related conditions, and for detecting doppel expression in a subject. Related compositions and methods also are described.
    Type: Grant
    Filed: June 17, 2021
    Date of Patent: February 27, 2024
    Assignee: PHAROSGEN CO., LTD
    Inventors: Youngro Byun, Ha Kyeong Lee, So Young Choi, So Ra Park, Se Ra Lee, Seung Il Baek
  • DOPPEL-TARGETING ANTIBODIES
    Publication number: 20220267422
    Abstract: Described herein are doppel-targeting molecules (e.g., antibodies) useful for inhibiting pathological angiogenesis and treating diseases and conditions associated with pathological angiogenesis, such as tumors, cancers, atherosclerosis, tuberculosis, asthma, pulmonary arterial hypertension (PAH), neoplasms and neoplasm-related conditions, and for detecting doppel expression in a subject. Related compositions and methods also are described.
    Type: Application
    Filed: June 17, 2021
    Publication date: August 25, 2022
    Applicant: PHAROSGEN CO., LTD
    Inventors: Youngro BYUN, Ha Kyeong LEE, So Young CHOI, So Ra PARK, Se Ra LEE, Seung Il BAEK
  • Methods of inhibiting pathological angiogenesis with doppel-targeting molecules
    Patent number: 10501549
    Abstract: Described herein are doppel-targeting molecules useful for inhibiting pathological angiogenesis and treating diseases and conditions associated with pathological angiogenesis, such as tumors, cancers, atherosclerosis, tuberculosis, asthma, pulmonary arterial hypertension (PAH), neoplasms and neoplasm-related conditions, and for detecting doppel expression in a subject. Related compositions and methods also are described.
    Type: Grant
    Filed: March 6, 2017
    Date of Patent: December 10, 2019
    Assignees: SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION, UNIVERSITY OF ULSAN, KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY, PHAROSGEN
    Inventors: Youngro Byun, In San Kim, Ahmed Al-Hilal Taslim, Sang-Yoon Kim, Ye Ji Jang
  • Prodrugs activated by caspase
    Patent number: 10357572
    Abstract: Described are prodrug conjugates that release a chemotherapeutic agent upon activation by caspase, and methods using such prodrug conjugates to induce apoptosis, amplify apoptosis, and treat cancer.
    Type: Grant
    Filed: August 29, 2017
    Date of Patent: July 23, 2019
    Assignee: PHAROSGEN CO., LTD.
    Inventors: Sang-Yoon Kim, Youngro Byun, Seung Woo Chung
  • Methods of inhibiting pathological angiogenesis with doppel-targeting molecules
    Patent number: 10202459
    Abstract: Described herein are doppel-targeting molecules useful for inhibiting pathological angiogenesis and treating diseases and conditions associated with pathological angiogenesis, such as tumors, cancers, atherosclerosis, tuberculosis, asthma, pulmonary arterial hypertension (PAH), neoplasms and neoplasm-related conditions, and for detecting doppel expression in a subject. Related compositions and methods also are described.
    Type: Grant
    Filed: November 29, 2016
    Date of Patent: February 12, 2019
    Assignees: SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION, UNIVERSITY OF ULSAN, KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY, PHAROSGEN
    Inventors: Youngro Byun, In San Kim, Ahmed Al-Hilal Taslim, Sang-Yoon Kim, Ye Ji Jang
  • PRODRUGS ACTIVATED BY CASPASE
    Publication number: 20180185498
    Abstract: Described are prodrug conjugates that release a chemotherapeutic agent upon activation by caspase, and methods using such prodrug conjugates to induce apoptosis, amplify apoptosis, and treat cancer.
    Type: Application
    Filed: August 29, 2017
    Publication date: July 5, 2018
    Applicant: Pharosgen Co., Ltd.
    Inventors: Sang-Yoon KIM, Youngro Byun, Seung Woo Chung
  • Prodrugs activated by caspase
    Patent number: 9775914
    Abstract: Described are prodrug conjugates that release a chemotherapeutic agent upon activation by caspase, and methods using such prodrug conjugates to induce apoptosis, amplify apoptosis, and treat cancer.
    Type: Grant
    Filed: July 10, 2015
    Date of Patent: October 3, 2017
    Assignee: PHAROSGEN CO., LTD.
    Inventors: Sang-Yoon Kim, Youngro Byun, Seung Woo Chung
  • METHODS OF INHIBITING PATHOLOGICAL ANGIOGENESIS WITH DOPPEL-TARGETING MOLECULES
    Publication number: 20170260278
    Abstract: Described herein are doppel-targeting molecules useful for inhibiting pathological angiogenesis and treating diseases and conditions associated with pathological angiogenesis, such as tumors, cancers, atherosclerosis, tuberculosis, asthma, pulmonary arterial hypertension (PAH), neoplasms and neoplasm-related conditions, and for detecting doppel expression in a subject. Related compositions and methods also are described.
    Type: Application
    Filed: March 6, 2017
    Publication date: September 14, 2017
    Applicants: SEOUL NATIONAL UNIVERSITY, UNIVERSITY OF ULSAN, KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY, PHAROSGEN
    Inventors: Youngro Byun, In San Kim, Ahmed Al-Hilal Taslim, Sang-Yoon Kim, Ye Ji Jang